Summary
The pharmacology, toxicity, and therapeutic effectiveness of etoposide (VP-16) given by the intrapleural route were examined in a phase I trial. Ten patients with malignant pleural effusion received 100, 150, or 225 mg/m2 VP-16 infused over 2 h into the pleural space after drainage of pleural fluid. The administration of VP-16 was tolerated well, with no local pain, increase in cough, dyspnea, or infection. Myelosuppression was mild at doses of 150 mg/m2 or less but severe at 225 mg/m2. Drug levels were followed in both plasma and pleural fluid for up to 12 h. Clearance of VP-16 from the pleural cavity was low at 2 ml/min m2. Peak pleural-fluid drug levels in patients receiving 225 mg/m2 exceeded 300 µg/ml, whereas peak drug concentrations in corresponding plasma samples obtained at the same time amounted to <10 µg/ml. Serial chest X-rays showed no disappearance of pleural effusion in nine evaluable patients. However, follow-up investigation of pleural fluid characteristics [carcinoembryonic antigen (CEA), lactic dehydrogenase (LDH), and cytologic examination] suggested some evidence of local therapeutic benefit.
Similar content being viewed by others
References
Alberts DS, Chen HSG, Mayersohn M, Perrier D, Moon TE, Gross JF (1979) Bleomycin pharmacokinetics in man: II. Intracavitary administration. Cancer Chemother Pharmacol 2: 127
Clarkson B, O’Connor A, Winston L, Hutchison D (1966) The physiologic disposition of 5-fluorouracil and 5-fluoro-2′-deoxyuridine in man. J Clin Pharmacol Ther 5: 581
D’Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Brambilla Pisoni M, Piazza E, Beer M, Cavalli F (1982) Pharmacokinetics of VP-16-123 given by different administration methods. Cancer Chemother Pharmacol 7: 141
Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G (1982) Pharmacokinetics of teniposide (VM-26) and etoposide (VP-16-213) in children with cancer. Cancer Chemother Pharmacol 7: 147
Howell SB, Chu BBF, Wung WE, Metha BM, Mendelsohn J (1981) Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161
Jones JM, Olman EA, Egorin MJ, Aisner J (1985) A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide. Cancer Chemother Pharmacol 14: 172
Markman M, Cleary S, King ME, Howell SB (1985) Cisplatin and cytarabine administered intrapleurally as treatment of malignant pleural effusions. Med Pediatr Oncol 13: 191
Ostrowski MJ, Halsall GM (1982) Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep 66: 1903
Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509
Sinkule JA, Hutson P, Hayes A, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumors. Cancer Res 44: 3109
Suhrland LG, Weisberger AS (1968) Intracavitary 5-fluorouracil in malignant effusions. Arch Intern Med 116: 431
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holoye, P.Y., Jeffries, D.G., Dhingra, H.M. et al. Intrapleural etoposide for malignant effusion. Cancer Chemother Pharmacol 26, 147–150 (1990). https://doi.org/10.1007/BF02897262
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897262